Trial · NCT02689856
Safety and Efficacy of Hydrocortisone and Lidocaine Treatment of Grade I and II Hemorrhoids
NCT02689856, Phase 2, Completed, Citius Pharmaceuticals, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety and Efficacy of Hydrocortisone and Lidocaine Treatment of Grade I and II Hemorrhoids. Trials, record NCT02689856. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02689856
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety and Efficacy of Hydrocortisone and Lidocaine Treatment of Grade I and II Hemorrhoids
- NCT number
- NCT02689856
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 211 participants, actual
- Lead sponsor
- Citius Pharmaceuticals, Inc.
- Conditions
- Hemorrhoids
- Interventions
- Hydrocortisone acetate and lidocaine hydrochloride, Placebo control, Hydrocortisone acetate, Lidocaine hydrochloride
- First posted
- 2016-02-24
- Last updated
- 2016-02-24
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Global score of disease severity | up to 14 days | A measure overall discomfort on a scale of 0 to 5 |
| Secondary | Individual signs and symptoms | up to 14 days | Has the subject received relief of pain, itching, bleeding or other reported symptoms evaluated on a scale of 0 to 5. |
| Secondary | Onset of relief of symptoms | 4 hours following product administration | How fast does the subject feel relief of symptoms measured in time after application of the drug. |
| Secondary | Recurrence of symptoms | 4 hours following product administration | When do the symptoms return measured in time after application of the drug. |
| Secondary | Severity and frequency of adverse events | 14 days | Assessment of severity and frequency of adverse events. |
| Secondary | Laboratory assessment | 14 days | Assessment of changes in blood chemistry, hematology and urinalysis at day 14 compared to baseline. |
| Secondary | Electrocardiography | 14 days | Assessment of changes in ECG parameters at day 14 compared to baseline. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02689856
GET https://conductscience.org/api/trials/v1/NCT02689856/registered